Healio (8/14, Carter) reports, “Use of lithium vs. valproate as a prophylactic treatment may be associated with adverse kidney outcomes, including AKI,” investigators concluded in a study that “examined data from the Stockholm Creatinine Measurements database, a health care use cohort of all adult Stockholm residents, and included 10,946 patients who began lithium or valproate therapy from January 2007 to December 2018.” Even though the study found that new “use of lithium was meaningfully associated with adverse kidney outcomes, with low absolute risks that did not differ between therapies,” it also revealed, however, that “elevated serum lithium levels were associated with future kidney risks, particularly AKI, emphasizing the need for close monitoring and lithium dose adjustment.” The findings were published online July 7 in JAMA Network Open.
Related Links:
— “Lithium therapy may be linked with AKI, poor kidney outcomes vs. valproate,”Shawn M. Carter, Healio, August 14, 2023